GUJTHEMGujarat Themis Biosyn Ltd.

    Gujarat Themis Biosyn Ltd: results and news

    Every Gujarat Themis Biosyn Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: credit rating, earnings.

    2 articles · Pharmaceutical intermediates and APIs · Latest 16 Nov 2026

    GUJTHEMGujarat Themis Biosyn Ltd.

    Gujarat Themis Biosyn Q2 FY27 Results: Consolidated Net Loss ₹13.84 Crore on Total Income of ₹53.72 Crore

    Gujarat Themis Biosyn (NSE: GUJTHEM) reported a consolidated total income of ₹53.72 crore and a net loss of ₹13.84 crore for the quarter ended 30 Sep 2026, it said in a filing on 14 Nov 2026. Standalone total income was ₹51.13 crore with a net profit of ₹8.47 crore for the same quarter.

    • Earnings
    • Pharmaceutical intermediates and APIs

    Blacklitt Research3 min read

    GUJTHEMGujarat Themis Biosyn Limited

    Themis Medicare’s bank facilities downgraded by CARE to BB+ (Stable) and A4+

    Themis Medicare Limited, which filed the intimation on 9 Oct 2026 through its Gujarat Themis Biosyn listing, has told the exchanges that CARE Ratings has downgraded the rating on its bank facilities. Long-term bank facilities of ₹77.39 crore are now CARE BB+; Stable, down from CARE BBB-; Negative, and short-term bank facilities of ₹48.50 crore are now CARE A4+, down from CARE A3.

    • Credit rating
    • Pharma

    Blacklitt Research1 min read